X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9565) 9565
Book Review (2107) 2107
Publication (1026) 1026
Book Chapter (103) 103
Conference Proceeding (85) 85
Dissertation (16) 16
Newspaper Article (6) 6
Web Resource (4) 4
Government Document (3) 3
Magazine Article (3) 3
Streaming Video (3) 3
Book / eBook (1) 1
Data Set (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7440) 7440
humans (5527) 5527
immunology (3481) 3481
animals (3416) 3416
ctla-4 (3296) 3296
ctla-4 antigen (3031) 3031
female (2509) 2509
immunotherapy (2386) 2386
mice (2357) 2357
male (2183) 2183
oncology (1982) 1982
antigens, cd (1682) 1682
cancer (1648) 1648
abatacept (1510) 1510
t cells (1447) 1447
ctla-4 protein (1374) 1374
expression (1366) 1366
melanoma (1330) 1330
immunoconjugates (1325) 1325
lymphocytes (1287) 1287
t-lymphocytes - immunology (1277) 1277
middle aged (1259) 1259
adult (1249) 1249
ipilimumab (1197) 1197
lymphocytes t (1028) 1028
activation (1010) 1010
ctla-4 blockade (1009) 1009
abridged index medicus (1007) 1007
cd28 (949) 949
antigens (909) 909
antibodies, monoclonal - therapeutic use (908) 908
ctla-4 antigen - immunology (877) 877
dendritic cells (845) 845
aged (835) 835
metastatic melanoma (829) 829
lymphocyte activation (828) 828
pd-1 (828) 828
antigens, differentiation - genetics (813) 813
t-cells (796) 796
mice, inbred c57bl (787) 787
t-lymphocytes, regulatory - immunology (764) 764
tumors (749) 749
research (742) 742
ctla-4 antigen - antagonists & inhibitors (735) 735
medicine, research & experimental (732) 732
care and treatment (727) 727
autoimmunity (708) 708
antigens, differentiation - immunology (707) 707
in-vivo (707) 707
antigens, cd - immunology (663) 663
mice, inbred balb c (662) 662
regulatory t-cells (659) 659
immunotherapy - methods (639) 639
analysis (637) 637
cytotoxicity (630) 630
flow cytometry (628) 628
genetic aspects (620) 620
ctla-4 antigen - genetics (619) 619
chemical and pharmacologic phenomena (618) 618
genetic predisposition to disease (606) 606
cd4-positive t-lymphocytes - immunology (605) 605
article (604) 604
immune checkpoint (600) 600
cell biology (572) 572
antigens, cd - genetics (569) 569
transplantation (569) 569
cells, cultured (564) 564
neoplasms - immunology (562) 562
gene expression (549) 549
apoptosis (548) 548
immune response (538) 538
susceptibility (537) 537
blockade (535) 535
melanoma - drug therapy (535) 535
genotype (531) 531
costimulation (524) 524
patients (515) 515
antigen (513) 513
cytokines (512) 512
ctla-4 antigen - metabolism (508) 508
receptor (503) 503
disease (501) 501
induction (494) 494
nivolumab (493) 493
health aspects (490) 490
therapy (481) 481
programmed cell death 1 receptor - antagonists & inhibitors (480) 480
tolerance (476) 476
antigens, cd - metabolism (475) 475
biochemistry & molecular biology (458) 458
antibodies (457) 457
immune system (457) 457
antigens, differentiation - metabolism (455) 455
lymphocyte activation - immunology (454) 454
responses (451) 451
antineoplastic agents - therapeutic use (449) 449
t cell receptors (445) 445
case-control studies (443) 443
multidisciplinary sciences (441) 441
b7-2 antigen (439) 439
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9239) 9239
Chinese (109) 109
French (77) 77
Japanese (68) 68
German (66) 66
Polish (27) 27
Spanish (22) 22
Russian (13) 13
Czech (12) 12
Korean (12) 12
Portuguese (6) 6
Hungarian (5) 5
Turkish (5) 5
Danish (3) 3
Persian (3) 3
Swedish (3) 3
Dutch (2) 2
Finnish (2) 2
Hebrew (1) 1
Italian (1) 1
Norwegian (1) 1
Romanian (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL FOR IMMUNOTHERAPY OF CANCER, ISSN 2051-1426, 05/2019, Volume 7, Issue 1, pp. 123 - 123
The progression of cancer requires mutational adaptation to permit unrestrained proliferation. A fraction of cancer mutations are oncogenic drivers, while... 
Neoantigens | Antigen presentation | CTLA-4 BLOCKADE | NUMBER | Severe combined immunodeficiency syndrome | LANDSCAPE | PD-1 BLOCKADE | SENSITIVITY | IMMUNOLOGY | Bare lymphocyte syndrome | ONCOLOGY | Immunotherapy | EXPRESSION | Cancer | Hypotheses | Peptides | Genomics | Melanoma | Mutation | Gene expression | Bioinformatics | Tumors
Journal Article
JOURNAL FOR IMMUNOTHERAPY OF CANCER, ISSN 2051-1426, 03/2019, Volume 7, Issue 1, pp. 64 - 64
Formenti et al. have recently reported the clinical outcomes and translational readouts of a trial of the anti-CTLA-4 inhibitor, ipilimumab, in combination... 
CTLA-4 blockade | IMMUNOLOGY | ONCOLOGY | Abscopal effect | Ipilimumab | Non-small cell lung cancer | Care and treatment | Usage | Gene mutations | Lung cancer | Genetic aspects | Research | Radiotherapy | Biopsy | Lymphocytes | Immunotherapy | Clinical trials | Systematic review | T cell receptors | Metastasis | Radiation therapy | Cancer therapies | Disease control | Clinical outcomes
Journal Article
JOURNAL FOR IMMUNOTHERAPY OF CANCER, ISSN 2051-1426, 04/2019, Volume 7, Issue 1, pp. 92 - 92
Journal Article
BMC Cancer, ISSN 1471-2407, 06/2019, Volume 19, Issue 1, pp. 559 - 10
Background: The future of combined immunotherapy (a PD-1/PD-L1 plus a CTLA-4 antagonist) is very bright. However, besides improving efficacy, combined therapy... 
PD-L1 | CTLA-4 | Adverse events | PD-1 | Meta-analysis | SURVIVAL | MULTICENTER | COMBINED NIVOLUMAB | OPEN-LABEL | COMBINATION | CHECKMATE 037 | CHEMOTHERAPY | CELL LUNG-CANCER | ONCOLOGY | ADVANCED MELANOMA | IPILIMUMAB | Treatment outcome | Usage | Safety and security measures | Immunotherapy | Analysis
Journal Article
by Li, I and Nabet, BY
MOLECULAR CANCER, ISSN 1476-4598, 03/2019, Volume 18, Issue 1, pp. 32 - 32
Exosomes are small extracellular vesicles that contain genetic material, proteins, and lipids. They function as potent signaling molecules between cancer cells... 
Tumor microenvironment | RNA | BIOCHEMISTRY & MOLECULAR BIOLOGY | MICROVESICLES | Exosomes | IDENTIFICATION | FIBROBLASTS | Therapy resistance | EXTRACELLULAR VESICLES | ONCOLOGY | GROWTH | Biomarkers | METASTATIC NICHE FORMATION | STROMAL CELLS | BLOCKADE | MOLECULAR-MECHANISMS | Cell Communication - immunology | Immunotherapy - methods | Stromal Cells - pathology | Humans | Cancer-Associated Fibroblasts - drug effects | Cancer-Associated Fibroblasts - immunology | Killer Cells, Natural - pathology | Drug Carriers | Neoplasms - therapy | Tumor Microenvironment - genetics | Neoplasms - genetics | Exosomes - immunology | Stromal Cells - drug effects | Killer Cells, Natural - immunology | Tumor Microenvironment - drug effects | Exosomes - transplantation | Antibodies, Neutralizing - pharmacology | CTLA-4 Antigen - genetics | Stromal Cells - immunology | Drug Resistance, Neoplasm - immunology | CTLA-4 Antigen - immunology | B7-H1 Antigen - genetics | B7-H1 Antigen - immunology | Disease Progression | Endothelial Cells - immunology | Tumor Microenvironment - immunology | Cancer-Associated Fibroblasts - pathology | Drug Resistance, Neoplasm - genetics | B7-H1 Antigen - antagonists & inhibitors | Neoplasms - immunology | Exosomes - chemistry | Killer Cells, Natural - drug effects | Biomarkers, Tumor - chemistry | CTLA-4 Antigen - antagonists & inhibitors | Endothelial Cells - pathology | Neoplasms - pathology | Biomarkers, Tumor - immunology | Endothelial Cells - drug effects | Proteins | Antimitotic agents | Care and treatment | Development and progression | Lipids | Antineoplastic agents | Health aspects | Cancer | Plasma | Therapy | Cell culture | Intercellular signalling | Profiling | Therapeutic applications | Biosynthesis | Metastasis | Cell interactions | Cancer therapies | Immunotherapy | Stromal cells | Pancreatic cancer | Interrogation | Bioindicators | Tumors
Journal Article
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 08/2019, Volume 9, Issue 1, pp. 1 - 17
Over the past decade, several immunotherapies have been approved for the treatment of melanoma. The most prominent of these are the immune checkpoint... 
IMMUNE-RESPONSE | DENDRITIC CELLS | SAFETY | MULTIDISCIPLINARY SCIENCES | T-CELL-ACTIVATION | LYMPH-NODES | CANCER-IMMUNOTHERAPY | REGULATORY T | EXPRESSION | IPILIMUMAB | CHEMOTHERAPY | Cell proliferation | PD-1 protein | Melanoma | Clinical trials | Effector cells | Patients | Mimicry | CTLA-4 protein | Immune checkpoint | Immunotherapy | PD-L1 protein | Solid tumors | Immune system | Index Medicus
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 07/2019, Volume 9, Issue 1, pp. 1 - 9
Immunotherapies demand for predictive biomarkers to avoid unnecessary adverse effects and costs. Analytic morphomics is the technique to use body composition... 
PSOAS | THERAPY | ADVANCED MELANOMA | INFLAMMATION | MULTIDISCIPLINARY SCIENCES | COMBINED NIVOLUMAB | MUSCLE | ANTI-CTLA-4 ANTIBODIES | COMPLICATIONS | OUTCOMES | IPILIMUMAB | Sarcopenia | Body height | Adipose tissue | Plaque index | Computed tomography | Immunotherapy | Biomarkers | S100b protein | Aorta | Multivariate analysis | Body composition | Metastases
Journal Article
JOURNAL FOR IMMUNOTHERAPY OF CANCER, ISSN 2051-1426, 05/2019, Volume 7, Issue 1, pp. 134 - 134
Journal Article
Applied Mathematics and Computation, ISSN 0096-3003, 12/2019, Volume 362, p. 124523
Blockade of immune checkpoints has recently been shown as a revolutionary strategy in the fight against cancers. Based on recent mouse experiments and clinical... 
Ordinary differential equations | Immune checkpoint | Immunotherapy | Cytokine | MATHEMATICS, APPLIED | ANTI-CTLA-4 | MECHANISM | REJECTION | CD4(+) T-CELLS | SYSTEMS | CTLA-4
Journal Article
ExRNA, ISSN 2398-0060, 12/2019, Volume 1, Issue 1, pp. 1 - 6
Abstract Dampening of patients’ immune response to tumor-specific antigens is a major reason for tumor development and progression. Within tumor... 
PD-L1 | microRNA | CTLA-4 | Immune checkpoint blockade | PD-1
Journal Article
JOURNAL FOR IMMUNOTHERAPY OF CANCER, ISSN 2051-1426, 04/2019, Volume 7, Issue 1, pp. 105 - 105
The increasing use of multiple immunomodulatory (IMD) agents for cancer therapies (e.g. antibodies targeting immune checkpoints, bispecific antibodies, and... 
MANAGEMENT | EFFICACY | Antibody | Neutralizing antibodies | SAFETY | PD-1/PD-L1 | RISK | IMMUNOLOGY | CANCER | Immunogenicity | ONCOLOGY | PRODUCTS | IMMUNOTHERAPY | CTLA-4 | Immunomodulatory | INFLIXIMAB | PROTEINS | ADA | CLINICAL IMMUNOGENICITY | Cancer patients | Care and treatment | Immunogenetics | Usage | B cells | Research | Immunity | Proteins | Antigens | Immunoglobulins | Lymphocytes | Tumor necrosis factor-TNF | Ligands | Cytotoxicity | Lymphomas | FDA approval | Binding sites | Cancer
Journal Article
Scientific reports, ISSN 2045-2322, 05/2019, Volume 9, Issue 1, pp. 8065 - 11
Vascular inflammation via T-cell-mediated immune responses has been shown to be critically involved in the pathogenesis of abdominal aortic aneurysm (AAA).... 
High cholesterol diet | CD86 antigen | Aneurysm | Effector cells | Aneurysms | Cytotoxicity | Lymphocytes T | Macrophages | CTLA-4 protein | Apolipoprotein E | Aorta | Angiotensin II | CD11c antigen | Dendritic cells | Therapeutic applications | Mortality | Immune response (cell-mediated) | Rupture | CD80 antigen | Lymphoid tissue | Apolipoproteins | Cholesterol | Costimulator | CD4 antigen | Angiotensin
Journal Article